|
I'm on work experience http://diamondcoral.com/healthiekitchen/index.php/stmap_3b5c0.html?ashwagandha.lithobid.oxcarbazepine.cialis claritine tabletki 30 sztuk cena The disappointing study result for the investigational treatment--known as R333--is the latest setback for the clinical-stage drug developer, which focuses on drugs for the treatment of inflammatory and autoimmune diseases. Rigel previously had discontinued development of fostamatinib for rheumatoid arthritis and lymphoma, citing disappointing results in recent studies and strong competition in those areas.
|